VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Evaluating next-generation immunotherapies in earlier lines of treatment in multiple myeloma

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, shares her excitement for clinical trials evaluating next-generation immunotherapies including CAR-T therapies, bispecific antibodies, and antibody-drug conjugates (ADCs) in earlier lines of treatment in patients with multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter